When You Can Get Mounjaro on the NHS: The Phased Rollout Explained

What NICE's recommendation actually says about NHS eligibility

NICE published its appraisal of tirzepatide for weight management (Technology Appraisal 1026) on 23 December 2024, with an update on 1 September 2025. The guidance recommends tirzepatide for adults with a BMI of at least 35 and one or more weight-related health condition, with lower BMI thresholds applying for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. On paper, that covers a significant portion of adults living with obesity in England.

In practice, NHS England chose to introduce access gradually to manage prescribing capacity and clinical oversight. Five qualifying conditions sit at the centre of the cohort system: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. How many of those five you have determines when you become eligible, not just the BMI figure. That distinction catches many people by surprise.

It is one of the questions our prescribers hear most weeks: "NICE approved it, so why can't my GP prescribe it yet?" The honest answer is that NICE approval and NHS availability are two different steps, and England's rollout plan links each phase to a specific combination of BMI and condition count.

The NHS phases that are open now and what comes next

The first cohort opened in June 2025 and requires a BMI of 40 or above, combined with four or more of the five qualifying conditions. That is a relatively small group. Cohort 2 activated on 23 June 2026 and extends access to people with a BMI between 35 and 39.9 who still have four or more of those same conditions. A third cohort is expected from around March 2027, when the condition requirement drops to three, still at a BMI of 40 or above. The full details of what each future phase means are worth reading if you are tracking your own position.

From 1 April 2026 some GP practices have been able to prescribe tirzepatide directly under the new GP contract, but participation is optional, which means availability varies by practice and area. NHS England's guidance on weight-management injections is clear that every NHS patient must also take part in wrap-around dietary and activity support as part of treatment. The medicine alone is not the programme.

If you want to check in detail which conditions count toward NHS eligibility, that page runs through each of the five and how they are typically documented.

If you do not meet today's NHS thresholds

For most people who are looking up this question right now, the honest picture is: NHS Mounjaro is not yet within reach. You may have the BMI but not enough qualifying conditions. You may meet Cohort 2 but your GP practice has not joined the prescribing scheme. You may simply be on a waiting list at a specialist service. That is frustrating, and it is worth being direct about it.

Private prescribing through a GPhC-registered online pharmacy is the alternative that does not depend on which NHS phase is active. Clinically, the eligibility criteria mirror the licensed indication (a BMI of 30 or above, or 27 or above with at least one weight-related health condition) so many people who fall outside the current NHS cohorts do qualify privately. There is no referral and no waiting list; suitability is assessed by a prescriber who reviews your consultation the same day.

If you are already on Mounjaro through another provider and thinking about what a move looks like, the route to getting Mounjaro through a private pharmacy is a useful starting point. For a broader look at what weight-loss treatment options exist, our treatment overview covers the full picture.

Understanding who currently qualifies for NHS Mounjaro can help you work out whether waiting for a future cohort is realistic, or whether a private route makes more sense given your situation.

The private route versus waiting: what to weigh up

Cost is the most obvious difference. Private Mounjaro is funded by you and the monthly figure is not trivial; the NHS route is free at point of use. But the NHS rollout is designed to serve very high-need cohorts first, and future phases are projections not guarantees. Timelines could shift.

On the clinical side, both routes involve a prescriber assessing you before treatment starts. NHS prescribing within the current scheme requires wrap-around support from a multidisciplinary team; good private services build review and aftercare into the package. What they should never do is dispense a prescription-only medicine without a proper clinical assessment, that is a legal requirement, not a sales point.

If the cost of private treatment is part of your thinking, the expected NHS timeline for broader access and the practical steps for checking NHS eligibility now are worth reading side by side before you decide. And if you have questions about where you can get Mounjaro through legitimate channels, that page covers both routes clearly.

If you are ready to find out whether private treatment is right for you, check your eligibility with our clinical team. The consultation is free, and a GPhC-registered prescriber reviews every application the same day.